Aptamer-Modified Magnetic Nanosensitizer for In Vivo MR Imaging of HER2-Expressing Cancer

Dan Heo, Minhee Ku, Jung Hoon Kim, Jaemoon Yang, Jinsuck Suh

Research output: Contribution to journalArticle

Abstract

The aim of this study was the development of a human epidermal growth factor receptor 2 (HER2)-targetable contrast agent for magnetic resonance imaging (MRI) with a high magnetic sensitivity. An anti-HER2 aptamer-modified magnetic nanosensitizer (Apt HER2 -MNS) was prepared by conjugation with 5′-thiol-modified aptamers and maleimidylated magnetic nanocrystals (MNCs). The physicochemical characteristics and targeting ability of Apt HER2 -MNS were confirmed, and the binding affinity (K d ) onto HER2 protein of Apt HER2 -MNS was 0.57 ± 0.26 nM. In vivo MRI contrast enhancement ability was also verified at HER2+ cancer cell (NIH3T6.7)-xenograft mouse models (n = 3) at 3T clinical MRI instrument. The control experiment was carried out using non-labeled MNCs. The results indicated that up to 150% contrast enhancement was achieved at the tumor region in the T2-weighted MR images after the injection of the Apt HER2 -MNS agent in mice that received the NIH3T6.7 cells.

Original languageEnglish
Article number288
JournalNanoscale Research Letters
Volume13
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

cancer
Imaging techniques
Magnetic resonance
magnetic resonance
Nanocrystals
mice
nanocrystals
human ERBB2 protein
Epidermal Growth Factor
augmentation
conjugation
Sulfhydryl Compounds
Heterografts
thiols
Contrast Media
affinity
Tumors
tumors
Cells
injection

All Science Journal Classification (ASJC) codes

  • Materials Science(all)
  • Condensed Matter Physics

Cite this

@article{bcefbd9714404353a96035ca9b2e68cf,
title = "Aptamer-Modified Magnetic Nanosensitizer for In Vivo MR Imaging of HER2-Expressing Cancer",
abstract = "The aim of this study was the development of a human epidermal growth factor receptor 2 (HER2)-targetable contrast agent for magnetic resonance imaging (MRI) with a high magnetic sensitivity. An anti-HER2 aptamer-modified magnetic nanosensitizer (Apt HER2 -MNS) was prepared by conjugation with 5′-thiol-modified aptamers and maleimidylated magnetic nanocrystals (MNCs). The physicochemical characteristics and targeting ability of Apt HER2 -MNS were confirmed, and the binding affinity (K d ) onto HER2 protein of Apt HER2 -MNS was 0.57 ± 0.26 nM. In vivo MRI contrast enhancement ability was also verified at HER2+ cancer cell (NIH3T6.7)-xenograft mouse models (n = 3) at 3T clinical MRI instrument. The control experiment was carried out using non-labeled MNCs. The results indicated that up to 150{\%} contrast enhancement was achieved at the tumor region in the T2-weighted MR images after the injection of the Apt HER2 -MNS agent in mice that received the NIH3T6.7 cells.",
author = "Dan Heo and Minhee Ku and Kim, {Jung Hoon} and Jaemoon Yang and Jinsuck Suh",
year = "2018",
month = "1",
day = "1",
doi = "10.1186/s11671-018-2682-3",
language = "English",
volume = "13",
journal = "Nanoscale Research Letters",
issn = "1931-7573",
publisher = "Springer New York",

}

Aptamer-Modified Magnetic Nanosensitizer for In Vivo MR Imaging of HER2-Expressing Cancer. / Heo, Dan; Ku, Minhee; Kim, Jung Hoon; Yang, Jaemoon; Suh, Jinsuck.

In: Nanoscale Research Letters, Vol. 13, 288, 01.01.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aptamer-Modified Magnetic Nanosensitizer for In Vivo MR Imaging of HER2-Expressing Cancer

AU - Heo, Dan

AU - Ku, Minhee

AU - Kim, Jung Hoon

AU - Yang, Jaemoon

AU - Suh, Jinsuck

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The aim of this study was the development of a human epidermal growth factor receptor 2 (HER2)-targetable contrast agent for magnetic resonance imaging (MRI) with a high magnetic sensitivity. An anti-HER2 aptamer-modified magnetic nanosensitizer (Apt HER2 -MNS) was prepared by conjugation with 5′-thiol-modified aptamers and maleimidylated magnetic nanocrystals (MNCs). The physicochemical characteristics and targeting ability of Apt HER2 -MNS were confirmed, and the binding affinity (K d ) onto HER2 protein of Apt HER2 -MNS was 0.57 ± 0.26 nM. In vivo MRI contrast enhancement ability was also verified at HER2+ cancer cell (NIH3T6.7)-xenograft mouse models (n = 3) at 3T clinical MRI instrument. The control experiment was carried out using non-labeled MNCs. The results indicated that up to 150% contrast enhancement was achieved at the tumor region in the T2-weighted MR images after the injection of the Apt HER2 -MNS agent in mice that received the NIH3T6.7 cells.

AB - The aim of this study was the development of a human epidermal growth factor receptor 2 (HER2)-targetable contrast agent for magnetic resonance imaging (MRI) with a high magnetic sensitivity. An anti-HER2 aptamer-modified magnetic nanosensitizer (Apt HER2 -MNS) was prepared by conjugation with 5′-thiol-modified aptamers and maleimidylated magnetic nanocrystals (MNCs). The physicochemical characteristics and targeting ability of Apt HER2 -MNS were confirmed, and the binding affinity (K d ) onto HER2 protein of Apt HER2 -MNS was 0.57 ± 0.26 nM. In vivo MRI contrast enhancement ability was also verified at HER2+ cancer cell (NIH3T6.7)-xenograft mouse models (n = 3) at 3T clinical MRI instrument. The control experiment was carried out using non-labeled MNCs. The results indicated that up to 150% contrast enhancement was achieved at the tumor region in the T2-weighted MR images after the injection of the Apt HER2 -MNS agent in mice that received the NIH3T6.7 cells.

UR - http://www.scopus.com/inward/record.url?scp=85053470085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053470085&partnerID=8YFLogxK

U2 - 10.1186/s11671-018-2682-3

DO - 10.1186/s11671-018-2682-3

M3 - Article

AN - SCOPUS:85053470085

VL - 13

JO - Nanoscale Research Letters

JF - Nanoscale Research Letters

SN - 1931-7573

M1 - 288

ER -